<DOC>
	<DOC>NCT01767298</DOC>
	<brief_summary>This study was conducted to compare the rate and extent of absorption of valsartan and hydrochlorothiazide. To maximize the possibility of finding drug-drug interactions, the dose of valsartan and hydrochlorothiazide was doubled (320 mg of VAL and 25 mg of HCT).</brief_summary>
	<brief_title>Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide (Double Doses)</brief_title>
	<detailed_description />
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>At least 18 years old and not more than 45 healthy male volunteers Actual weight no more than Â± 30% from ideal body weight based on sex, height, and body frame Who had passed all the screening parameters Free of any drug exposure known to interfere with the pharmacokinetics or assay of fexofenadine for at least 10 days prior to the study Who had to be able to communicate effectively with study personnel, be literate, and able to give consent. A clinically significant abnormal physical exam, medical history, or laboratory studies If they showed a sitting SBP of &gt;140 or &lt;100 mmHg, DBP &gt; 90 or &lt;60mm Hg, or a pulse rate of &gt; 95 or &lt; 50 beats/min at screening A history of serious intolerance, allergy, or sensitivity to fexofenadine The use of any prescription drug within the previous month or use of any overthecounter medication (with the exception of acetaminophen) within the past 14 days A history of blood dyscrasias A history of alcohol or drug abuse within the past year Donation of blood during the 8 weeks prior to the study or plans to donate blood during or within 8 weeks of completing the study Unable to tolerate vein puncture and multiple blood samplings Any surgical/medical condition that might alter drug absorption, distribution, metabolism, or excretion Cannot follow instructions, in the opinion of the investigator.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Fixed dose combination</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Valsartan</keyword>
	<keyword>Hydrochlorothiazide</keyword>
</DOC>